Viking Leads Tiger-Related Funds in Latest Biopharma IPO

Viking and Matrix Capital Management are the largest outside investors in Adaptive Biotechnologies.

Illustration by II

Illustration by II

A company that counts several prominent hedge funds from the Tiger Management crowd among its major investors has filed plans to go public.

But it is not a unicorn or an internet, technology, or new media company.

Rather, it is the latest among a growing number of fledgling biopharma companies looking to raise money in the public markets.

To continue reading, subscribe now to Premium Journalism. Already a subscriber? login.

Related